The New, New 510(k) Paradigm: Special 510(k)s

by | Sep 16, 2019 | 510k, FDA, Medical Devices, Quality Systems, Regulatory, Requirements

The Special 510(k) program was established to create a more efficient review process (30 days instead of the 90 days for Traditional 510(k)s!) for certain changes subject to 510(k) submission requirements. FDA released a new guidance document that supersedes the Special 510(k) content in “The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications,” issued on March 20, 1998.  What are some of the changes? Read on.

The Special 510(k) program facilitates the review of certain changes by leveraging design control requirements. Thus, manufacturers can use risk analysis and verification and validation activities to facilitate the review and clearance for the change(s). In the past, a change in intended use or fundamental scientific technology would not be appropriate under a Special 510(k). In the new guidance (“The Special 510(k) Program”), FDA explains a shift to determining whether methods to evaluate the change(s) are well-established and whether results can be reviewed in a summary or risk analysis format. The guidance document outlines some guiding questions when considering whether a 510(k) is appropriate for review as a Special 510(k):

  1. Is it a change to the manufacturer’s own device?

A Special 510(k) can only be submitted for a proposed change by the manufacturer who is legally authorized to market the existing device.

  1. Are performance data needed to evaluate the change?

If performance data is not needed to evaluate the change, a Special 510(k) may be appropriate.

  1. If performance data is needed to evaluate the change, are there well-established methods available?

This can be the submitter’s methods used previously, internationally recognized standards, qualified medical device development tools, or scientifically accepted methods.

  1. If performance data is needed, can the data be reviewed in a summary or risk analysis format?

FDA should not have to review all the data to understand if they support substantial equivalence.

FDA outlines when a 510(k) may not be appropriate, including:

  • Evaluation involves greater than 3 scientific disciplines (e.g., biocompatibility, sterility, EMC)
  • Quality System inspection identified violations that relate to design controls that are relevant to the design changes under review in the 510(k)
  • Changes of indications that require review of clinical, animal, or cadaver data
  • Novel sterilization methods

If FDA finds that a Special 510(k) is not appropriate, FDA may convert the submission to a Traditional 510(k). However, this can result in delayed review timelines because the submissions require different elements.

The newly released guidance document includes examples of changes that may or may not be appropriate for the Special 510(k) route, as well as recommended content for a Special 510(k) submission.

Have any questions about this new paradigm? Do you need help with your 510k submission? Contact us at 248-987-4497 or email: info@emmainternational.com.

Song Seto, Ph.D.

Song Seto, Ph.D.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This